University of North Texas Health Science Center, Institute for Healthy Aging, Center for Neuroscience Discovery, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, United States.
University of North Texas Health Science Center, Institute for Healthy Aging, Center for Neuroscience Discovery, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, United States.
Brain Res Bull. 2017 Sep;134:168-176. doi: 10.1016/j.brainresbull.2017.07.018. Epub 2017 Jul 27.
Tremendous efforts and funds invested in discovery of novel drug treatments for ischemic stroke have so far failed to deliver clinically efficacious therapies. The reasons for these failures are not fully understood. An indiscriminate use of isoflurane-based surgical anesthesia with or without nitrous oxide may act as an unconstrained, untraceable source of data variability, potentially causing false-positive or false-negative results. To test this hypothesis, a common transient suture middle cerebral artery occlusion (tMCAO) model of ischemic stroke in young adult male rats was used to determine the impact of a typical range of anesthesia durations required for this model on data variability (i.e., infarct volume and neurological deficits). The animals were maintained on spontaneous ventilation. The study results indicated that: (1) Variable duration of isoflurane anesthesia prior, during and after tMCAO is a significant source of data variability as evidenced by measurements of infarct volume and neurological deficits; and (2) Severity of brain injury and neurological deficits after tMCAO is inversely related to the duration of isoflurane anesthesia: e.g., in our study, a 90min isoflurane anesthesia nearly completely protected brain tissues from tMCAO-induced injury and thus, would be expected to obscure the effects of stroke treatments in pre-clinical trials. To elevate transparency, rigor and reproducibility of stroke research and minimize undesirable effects of isoflurane on the outcome of novel drug testing, we propose to monitor, minimize and standardize isoflurane anesthesia in experimental surgeries and make anesthesia duration a required reportable parameter in pre-clinical studies. Specifically, we propose to adopt 20-30min as an optimal anesthesia duration that both minimizes neuroprotective effects of isoflurane and permits a successful completion of surgical procedures in a suture tMCAO model of ischemic stroke in rodents. As the mechanisms and neuroprotective, metabolic and immune effects of general anesthesia are not fully understood, the results of this study cannot be blindly generalized to other anesthetics, animal species and experimental models.
尽管在发现新型缺血性脑卒中治疗药物方面投入了巨大的努力和资金,但迄今为止,仍未能提供临床有效的治疗方法。这些失败的原因尚未完全阐明。在没有或有一氧化二氮的情况下,盲目使用异氟烷为基础的手术麻醉可能会成为一个不受限制、无法追踪的数据源,从而导致假阳性或假阴性结果。为了验证这一假设,我们使用了一种常见的成年雄性大鼠短暂性缝扎大脑中动脉阻塞(tMCAO)缺血性脑卒中模型,以确定该模型所需的典型麻醉持续时间范围对数据变异性(即梗死体积和神经功能缺损)的影响。动物在自主呼吸下维持。研究结果表明:(1)tMCAO 术前、术中和术后异氟烷麻醉持续时间的变化是数据变异性的一个重要来源,这可以通过测量梗死体积和神经功能缺损来证明;(2)tMCAO 后脑损伤和神经功能缺损的严重程度与异氟烷麻醉持续时间呈反比:例如,在我们的研究中,90 分钟的异氟烷麻醉几乎完全保护脑组织免受 tMCAO 引起的损伤,因此,在临床前试验中可能会掩盖脑卒中治疗的效果。为了提高脑卒中研究的透明度、严谨性和可重复性,并最大限度地减少异氟烷对新型药物测试结果的不良影响,我们建议在实验手术中监测、最小化和标准化异氟烷麻醉,并将麻醉持续时间作为临床前研究中必需的报告参数。具体来说,我们建议采用 20-30 分钟作为最佳麻醉持续时间,既能最大限度地减少异氟烷的神经保护作用,又能在啮齿动物缺血性脑卒中缝扎大脑中动脉阻塞模型中成功完成手术。由于全身麻醉的机制和神经保护、代谢和免疫作用尚未完全阐明,因此,这项研究的结果不能盲目推广到其他麻醉剂、动物物种和实验模型。